1. Microinjection of urotensin II into the rostral ventrolateral medulla increases sympathetic vasomotor tone via the GPR14/ERK pathway in rats.
- Author
-
Cao YK, Guo Q, Ma HJ, Wang R, Teng X, and Wu Y
- Subjects
- Animals, Blood Pressure drug effects, Heart Rate drug effects, MAP Kinase Signaling System drug effects, Male, Medulla Oblongata metabolism, Rats, Rats, Sprague-Dawley, Sympathetic Nervous System metabolism, Medulla Oblongata drug effects, Receptors, G-Protein-Coupled metabolism, Signal Transduction drug effects, Sympathetic Nervous System drug effects, Urotensins administration & dosage
- Abstract
The present study aimed to reveal the effects of urotensin II (UII) on sympathetic vasomotor tone in the rostral ventrolateral medulla (RVLM). UII (0.3, 3, and 30 nmol/L, 50 nL) was microinjected into the RVLM. Blood pressure (BP), heart rate (HR), and renal sympathetic nerve activity (RSNA) were measured to determine the sympathetic vasomotor tone. BP, HR, and RSNA were simultaneously recorded after drugs had been microinjected into the RVLM. Microinjection of UII (0.3, 3, and 30 nmol/L, 50 nL) into the RVLM significantly increased BP, HR, and RSNA. Pretreatment with BIM23127 (300 nmol/L, 50 nL), a potent antagonist of the UII receptor GPR14, abolished the effect of UII. Previous microinjection of PD98059 (25 μmol/L, 50 nL), an inhibitor of ERK, significantly suppressed the effects of UII. Preinjection of an inhibitor of the N-type Ca
2+ channel, ω-conotoxin GVIA (50 nmol/L, 50 nL), inhibited the effects of UII. The present study demonstrated that microinjection of UII into the RVLM significantly increased sympathetic vasomotor tone, which was mediated by the GPR14/ERK/N-type Ca2+ channel pathway. UII may become a novel therapeutic target for autonomic nervous system regulation, especially in hypertension.- Published
- 2020
- Full Text
- View/download PDF